Cargando…
SUN-383 Sustained Clinical Improvement after Discontinuation of Mifepristone: Unexpected Remission of Hypercortisolism
Background: The competitive GR antagonist mifepristone (MIFE, Korlym®, Corcept Therapeutics) has been used in the treatment of patients with hypercortisolism of unknown origin. In most patients, symptoms (e.g., hyperglycemia, weight gain, or psychiatric symptoms) return within several weeks if MIFE...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553289/ http://dx.doi.org/10.1210/js.2019-SUN-383 |